Windward Bio Group AG is a clinical-stage biopharmaceutical company focused on the discovery, licensing, and clinical development of differentiated, ultra-long-acting biologic therapeutics targeting clinically validated immunological pathways. The company operates primarily from Basel, Switzerland, with corporate operations also established in the United States, and holds commercialization rights to its clinical-stage assets outside Greater China. Windward Bio operates in a single operating segment focused on research and drug development and is pre-revenue, having generated no commercial product sales since inception. Its pipeline is anchored by two primary clinical assets: WIN378, an ultra-long-acting fully human monoclonal antibody designed to inhibit TSLP, currently being evaluated in a Phase 2/3 study (POLARIS-1) for severe uncontrolled asthma and a Phase 2 study (SIRIUS) for COPD with a target twice-yearly subcutaneous dosing regimen; and WIN027, an investigational long-acting bispecific antibody designed to neutralize both TSLP and IL-13 simultaneously, undergoing Phase 1 evaluation with planned Phase 2 studies in COPD and atopic dermatitis. The company also maintains internal discovery research to feed its pipeline of bispecific antibodies. Windward Bio targets substantial therapeutic markets including severe asthma, COPD, and atopic dermatitis, competing against approved biologic standards of care such as tezepelumab (Tezspire) and dupilumab (Dupixent). Its competitive positioning centers on optimized molecular design aimed at substantially longer dosing intervals (e.g., semi-annual subcutaneous injections) and dual-pathway cytokine inhibition, designed to improve real-world treatment adherence and disease control.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!